HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS REGISTER		Author Keyword(s) Vol Page [Advanced]

This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this link to a friend Similar articles in this journal Similar articles in PubMed Add article to my folders Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Baughman, R. P Articles by Lower, E. E Search for Related Content PubMed PubMed Citation Articles by Baughman, R. P Articles by Lower, E. E

Thorax 1999;54:742-746 ( August )

Occasional review

A clinical approach to the use of methotrexate for sarcoidosis

Robert P Baughman, Elyse E Lower

Department of Internal Medicine, University of Cincinnati Medical Center, Cincinnati, Ohio 45267-0564, USA

Correspondence to: Dr R P Baughman.

The first 150 words of the full text of this article appear below.

	Article

The management of patients with sarcoidosis has been the subject of many papers in this¹ and other journals.^2-5 The large number of papers are, in part, because of the difficulty in defining who should be treated for this disease and with what. The most commonly used pharmaceutical class for sarcoidosis has been corticosteroids, both topically and systemically.⁶ The use of systemic steroids for sarcoidosis was the subject of a trial by the British Thoracic Society¹ which concluded that there were some patients who required no treatment and some who would need immediate treatment because of the severity of the disease. In between was a group of patients with persistent disease who appeared to benefit from treatment with corticosteroids. One of the points made was that some patients needed treatment for long periods of time.

The term "chronic sarcoidosis" has been used by Dr Geraint James to describe patients with disease . . . [Full text of this article]

This article has been cited by other articles:

				M. A. Judson, R. P. Baughman, U. Costabel, S. Flavin, K. H. Lo, M. S. Kavuru, M. Drent, and the Centocor T48 Sarcoidosis investigators Efficacy of infliximab in extrapulmonary sarcoidosis: results from a randomised trial Eur. Respir. J., June 1, 2008; 31(6): 1189 - 1196. [Abstract] [Full Text] [PDF]

				A. F. Shorr, D. L. Helman, D. B. Davies, and S. D. Nathan Pulmonary hypertension in advanced sarcoidosis: epidemiology and clinical characteristics Eur. Respir. J., May 1, 2005; 25(5): 783 - 788. [Abstract] [Full Text] [PDF]

				R. P. Baughman, A. Koehler, P. A. Bejarano, E. E. Lower, and F. L. Weber Jr Role of Liver Function Tests in Detecting Methotrexate-Induced Liver Damage in Sarcoidosis Arch Intern Med, March 10, 2003; 163(5): 615 - 620. [Abstract] [Full Text] [PDF]

				U. Costabel Sarcoidosis: clinical update Eur. Respir. J., July 1, 2001; 18(32_suppl): 56S - 68s. [Abstract] [Full Text] [PDF]

				G J GIBSON Sarcoidosis: old and new treatments Thorax, May 1, 2001; 56(5): 336 - 339. [Full Text]